[Reduction of infarct size and remodeling after ramipril].
It is known that angiotensin converting enzyme (ACE) inhibitors not only prevent the formation of angiotensin II, but also potentiate the activity of bradykinin. We investigated the effects of the ACE-inhibitor ramipril in two models of cardiac ischemia. In anesthetized dogs with a coronary occlusion of 6-h duration, both ramiprilat and bradykinin significantly reduced infarct-size. This effect was prevented by the co-administration of the bradykinin antagonist HOE 140. In rats with a coronary occlusion of 6-weeks duration, ramipril administration significantly reduced infarct-size and prevented the development of left ventricular hypertrophy. Thus, ramipril showed a cardioprotective activity in models of acute as well as of chronic myocardial ischemia. These effects are probably mediated by the potentiation of bradykinin.
Cassella AG, SGE Herz-Kreislauf Therapeutika, Frankfurt/Main.
P A
PA
Martorana
W
W
Linz
B A
BA
Schölkens
D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000473:pathology; D009203:Myocardial Infarction / Q000473:pathology*; D009206:Myocardium / Q000473:pathology; D017257:Ramipril / Q000494:pharmacology*; D051381:Rats
C065679:icatibant; D017257:Ramipril; D001920:Bradykinin
Infarktgrössenverminderung und Remodeling nach Ramipril.